Because of this epigenetic dysregulation involving overexpression of HDAC1, HDAC2, HDAC3, and LSD1, we anticipate that the 4SC-202, which specifically targets Class I HDACs (HDAC1, HDAC2, HDAC3, HDAC8) and LSD1, may selectively affect ATRT tumor cells. This evidence concerns the gene HDAC3 and neoplasm.